NCT04291261View on ClinicalTrials.gov

Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

June 24, 2024

Study Completion Date

June 30, 2025

Conditions
Acute-graft-versus-host Disease
Interventions
DRUG

Uvadex

Extracorporeal photopheresis (ECP) with Uvadex is scheduled 3x/week in weeks 1+2, 2x/week thereafter till day 28 and 1x/week till day 56

Trial Locations (4)

8036

Medical University of Graz, Department of Internal Medicine, Graz

20246

University Medical Center Hamburg-Eppendorf, Hamburg

91054

University Hospital Erlangen, Erlangen

93053

University Medical Center Regensburg, Regensburg

All Listed Sponsors
collaborator

Therakos

INDUSTRY

collaborator

University Medical Center Regensburg

UNKNOWN

collaborator

Arbeitskreis Klinische Forschung PD Dr. med. Seiler GmbH

NETWORK

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER